A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Study ID
NCT06794268
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lisocabtagene maraleucel — BIOLOGICAL
    As per product label

Study Details

The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Key Dates

Start date
Feb 4, 2025
Status verified
Feb 2025
Primary completion
Aug 31, 2044
Completion
Aug 31, 2044

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Participants receiving lisocabtagene maraleucel treatment

Primary Outcome Measure

Incidence of adverse events (AEs) of interest [ Time Frame: Up to 15 years ]

Central Contacts

  • BMS Study Connect Contact Center www.BMSStudyConnect.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (1)

FacilityCityStateZIPSite coordinators
CIBMTRMilwaukeeWisconsin53226-

Find similar trials in Milwaukee, WI

By research site
CIBMTR· Milwaukee, WI

Related Studies